Xilio Therapeutics (XLO) EBITDA (2020 - 2026)

Xilio Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$9.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$9.5 million, up 28.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$31.3 million (up 42.36% YoY), and the FY2025 annual result was -$35.0 million, up 39.84% from the prior year.
• EBITDA came in at -$9.5 million for Q1 2026 at Xilio Therapeutics, down from $10.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $10.4 million in Q4 2025 to a low of -$24.6 million in Q2 2022.
• The 5-year median for EBITDA is -$16.7 million (2023), against an average of -$15.7 million.
• Across the five-year window, EBITDA declined 28.12% in 2022 and surged 179.13% in 2025, its largest moves.
• Xilio Therapeutics' EBITDA stood at -$22.5 million in 2022, then climbed by 21.41% to -$17.7 million in 2023, then grew by 25.84% to -$13.1 million in 2024, then soared by 179.13% to $10.4 million in 2025, then tumbled by 191.98% to -$9.5 million in 2026.
• The last three EBITDA figures came in at -$9.5 million (Q1 2026), $10.4 million (Q4 2025), and -$16.3 million (Q3 2025), per Business Quant data.